Overview

Promising ROd-cone DYstrophy Gene therapY

Status:
Not yet recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm controlled double-masked randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
SparingVision